|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kandoth C, Schultz N, Cherniack AD, Akbani
R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, et al
Cancer Genome Atlas Research Network: Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gadducci A, Cosio S and Genazzani AR: Old
and new perspectives in the pharmacological treatment of advanced
or recurrent endometrial cancer: Hormonal therapy, chemotherapy and
molecularly targeted therapies. Crit Rev Oncol Hematol. 58:242–256.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lahiri T, Laporte JD, Moore PE, Panettieri
RA Jr and Shore SA: Interleukin-6 family cytokines: Signaling and
effects in human airway smooth muscle cells. Am J Physiol Lung Cell
Mol Physiol. 280:L1225–L1232. 2001.PubMed/NCBI
|
|
5
|
Grenier A, Dehoux M, Boutten A,
Arce-Vicioso M, Durand G, Gougerot-Pocidalo MA and Chollet-Martin
S: Oncostatin M production and regulation by human
polymorphonuclear neutrophils. Blood. 93:1413–1421. 1999.PubMed/NCBI
|
|
6
|
Horn D, Fitzpatrick WC, Gompper PT, Ochs
V, Bolton-Hansen M, Zarling J, Malik N, Todaro GJ and Linsley PS:
Regulation of cell growth by recombinant oncostatin M. Growth
Factors. 2:157–165. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Douglas AM, Goss GA, Sutherland RL, Hilton
DJ, Berndt MC, Nicola NA and Begley CG: Expression and function of
members of the cytokine receptor superfamily on breast cancer
cells. Oncogene. 14:661–669. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brounais B, Chipoy C, Mori K, Charrier C,
Battaglia S, Pilet P, Richards CD, Heymann D, Rédini F and
Blanchard F: Oncostatin M induces bone loss and sensitizes rat
osteosarcoma to the antitumor effect of Midostaurin in vivo. Clin
Cancer Res. 14:5400–5409. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Godoy-Tundidor S, Cavarretta IT, Fuchs D,
Fiechtl M, Steiner H, Friedbichler K, Bartsch G, Hobisch A and
Culig Z: Interleukin-6 and oncostatin M stimulation of
proliferation of prostate cancer 22Rv1 cells through the signaling
pathways of p38 mitogen-activated protein kinase and
phosphatidylinositol 3-kinase. Prostate. 64:209–216. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Q, Zhu J, Sun F, Liu L, Liu X and Yue
Y: Oncostatin M promotes proliferation of ovarian cancer cells
through signal transducer and activator of transcription 3. Int J
Mol Med. 28:101–108. 2011.PubMed/NCBI
|
|
11
|
Mori S, Murakami-Mori K and Bonavida B:
Oncostatin M (OM) promotes the growth of DU 145 human prostate
cancer cells, but not PC-3 or LNCaP, through the signaling of the
OM specific receptor. Anticancer Res. 19:1011–1015. 1999.PubMed/NCBI
|
|
12
|
Gearing DP and Bruce AG: Oncostatin M
binds the high-affinity leukemia inhibitory factor receptor. New
Biol. 4:61–65. 1992.PubMed/NCBI
|
|
13
|
Gearing DP, Comeau MR, Friend DJ, Gimpel
SD, Thut CJ, McGourty J, Brasher KK, King JA, Gillis S, Mosley B,
et al: The IL-6 signal transducer, gp130: An oncostatin M receptor
and affinity converter for the LIF receptor. Science.
255:1434–1437. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mosley B, De Imus C, Friend D, Boiani N,
Thoma B, Park LS and Cosman D: Dual oncostatin M (OSM) receptors.
Cloning and characterization of an alternative signaling subunit
conferring OSM-specific receptor activation. J Biol Chem.
271:32635–32643. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Niu G, Wright KL, Huang M, Song L, Haura
E, Turkson J, Zhang S, Wang T, Sinibaldi D, Coppola D, et al:
Constitutive Stat3 activity up-regulates VEGF expression and tumor
angiogenesis. Oncogene. 21:2000–2008. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Folkman J: Angiogenesis in cancer,
vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Risau W: Mechanisms of angiogenesis.
Nature. 386:671–674. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Creasman W: Revised FIGO staging for
carcinoma of the endometrium. Int J Gynaecol Obstet. 105:1092009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liao Y, Lu W, Che Q, Yang T, Qiu H, Zhang
H, He X, Wang J, Qiu M, Zou Y, et al: SHARP1 suppresses
angiogenesis of endometrial cancer by decreasing hypoxia-inducible
factor-1α level. PLoS One. 9:e999072014. View Article : Google Scholar
|
|
20
|
Calò V, Migliavacca M, Bazan V, Macaluso
M, Buscemi M, Gebbia N and Russo A: STAT proteins: From normal
control of cellular events to tumorigenesis. J Cell Physiol.
197:157–168. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim KJ, Li B, Winer J, Armanini M, Gillett
N, Phillips HS and Ferrara N: Inhibition of vascular endothelial
growth factor-induced angiogenesis suppresses tumour growth in
vivo. Nature. 362:841–844. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tanaka M and Miyajima A: Oncostatin M, a
multifunctional cytokine. Rev Physiol Biochem Pharmacol. 149:39–52.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Uharcek P: Prognostic factors in
endometrial carcinoma. J Obstet Gynaecol Res. 34:776–783. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hirai M, Nakagawara A, Oosaki T, Hayashi
Y, Hirono M and Yoshihara T: Expression of vascular endothelial
growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal
uterine endometrial carcinoma. Gynecol Oncol. 80:181–188. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kamat AA, Merritt WM, Coffey D, Lin YG,
Patel PR, Broaddus R, Nugent E, Han LY, Landen CN Jr, Spannuth WA,
et al: Clinical and biological significance of vascular endothelial
growth factor in endometrial cancer. Clin Cancer Res. 13:7487–7495.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yokoyama Y, Sato S, Futagami M, Fukushi Y,
Sakamoto T, Umemoto M and Saito Y: Prognostic significance of
vascular endothelial growth factor and its receptors in endometrial
carcinoma. Gynecol Oncol. 77:413–418. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Haura EB, Zheng Z, Song L, Cantor A and
Bepler G: Activated epidermal growth factor receptor-Stat-3
signaling promotes tumor survival in vivo in non-small cell lung
cancer. Clin Cancer Res. 11:8288–8294. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang R, Jin Z, Liu Z, Sun L, Wang L and
Li K: Correlation of activated STAT3 expression with
clinicopathologic features in lung adenocarcinoma and squamous cell
carcinoma. Mol Diagn Ther. 15:347–352. 2011. View Article : Google Scholar
|
|
29
|
Seethala RR, Gooding WE, Handler PN,
Collins B, Zhang Q, Siegfried JM and Grandis JR:
Immunohistochemical analysis of phosphotyrosine signal transducer
and activator of transcription 3 and epidermal growth factor
receptor autocrine signaling pathways in head and neck cancers and
metastatic lymph nodes. Clin Cancer Res. 14:1303–1309. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gong W, Wang L, Yao JC, Ajani JA, Wei D,
Aldape KD, Xie K, Sawaya R and Huang S: Expression of activated
signal transducer and activator of transcription 3 predicts
expression of vascular endothelial growth factor in and angiogenic
phenotype of human gastric cancer. Clin Cancer Res. 11:1386–1393.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lee J, Kang WK, Park JO, Park SH, Park YS,
Lim HY, Kim J, Kong J, Choi MG, Sohn TS, et al: Expression of
activated signal transducer and activator of transcription 3
predicts poor clinical outcome in gastric adenocarcinoma. APMIS.
117:598–606. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lassmann S, Schuster I, Walch A, Göbel H,
Jütting U, Makowiec F, Hopt U and Werner M: STAT3 mRnA and protein
expression in colorectal cancer: Effects on STAT3-inducible targets
linked to cell survival and proliferation. J Clin Pathol.
60:173–179. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Morikawa T, Baba Y, Yamauchi M, Kuchiba A,
Nosho K, Shima K, Tanaka N, Huttenhower C, Frank DA, Fuchs CS, et
al: STAT3 expression, molecular features, inflammation patterns,
and prognosis in a database of 724 colorectal cancers. Clin Cancer
Res. 17:1452–1462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fossey SL, Bear MD, Kisseberth WC, Pennell
M and London CA: Oncostatin M promotes STAT3 activation, VEGF
production, and invasion in osteosarcoma cell lines. BMC Cancer.
11:1252011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chipoy C, Berreur M, Couillaud S, Pradal
G, Vallette F, Colombeix C, Rédini F, Heymann D and Blanchard F:
Downregulation of osteoblast markers and induction of the glial
fibrillary acidic protein by oncostatin M in osteosarcoma cells
require PKCdelta and STAT3. J Bone Miner Res. 19:1850–1861. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chipoy C, Brounais B, Trichet V, Battaglia
S, Berreur M, Oliver L, Juin P, Rédini F, Heymann D and Blanchard
F: Sensitization of osteosarcoma cells to apoptosis by oncostatin M
depends on STAT5 and p53. Oncogene. 26:6653–6664. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
David E, Tirode F, Baud’huin M, Guihard P,
Laud K, Delattre O, Heymann MF, Heymann D, Redini F and Blanchard
F: Oncostatin M is a growth factor for Ewing sarcoma. Am J Pathol.
181:1782–1795. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Amaral MC, Miles S, Kumar G and Nel AE:
Oncostatin-M stimulates tyrosine protein phosphorylation in
parallel with the activation of p42MAPK/ERK-2 in Kaposi’s cells.
Evidence that this pathway is important in Kaposi cell growth. J
Clin Invest. 92:848–857. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lauber S1, Wong S, Cutz JC, Tanaka M,
Barra N, Lhoták S, Ashkar A and Richards CD: Novel function of
Oncostatin M as a potent tumour-promoting agent in lung. Int J
Cancer. 136:831–843. 2015. View Article : Google Scholar
|
